Purpose: L-asparaginase is a crucial chemotherapeutic agent for the treatment of acute lymphoblastic leukemia. However, hypersensitivity to L-asparaginase is common which limits its clinical use. Methods: We performed 44 cases of premedication and 3 cases of desensitization in 16 patients with hypersensitivity to L-asparaginase. Results: With premedication, 33 cases completed L-asparaginase injection with no hypersensitivity reactions. Eleven cases showed mild hypersensitivity reactions, such as urticaria. Desensitization was performed in 3 cases: in 2 cases, desensitization was successful, and in 1 case the medication was switched to Erwinia asparaginase. 
Total dose in solution C is calculated by subtracting the cumulative dose administered in steps 1-8 from the total desired dose. Solutions were prepared by the Pharmacy Department Cytotoxic Unit and then spiked at bedside by the specialized nursing staff with an individual infusion line. Fig. 2 ). Fig. 2 ). 
탈감작 결과

3건의 탈감작을 시행하였으며 프로토콜은
고 찰 E. coli-아스파라기나제는 ALL치료에 중요한 역할을 하는 약물 이지만 E. coli-아스파라기나제에 대한 과민반응이 흔하여 치료에 어려움을 겪고 있다. 본 연구 결과를 토대로 E. coli-아스파라기나제
